An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens
Titel:
An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens
Auteur:
Parma, Gabriella Mancari, Rosanna Del Conte, Gianluca Scambia, Giovanni Gadducci, Angiolo Hess, Dagmar Katsaros, Dionyssios Sessa, Cristiana Rinaldi, Andrea Bertoni, Francesco Vitali, Andrea Catapano, Carlo Vittorio Marsoni, Silvia van de Velde, Helgi Colombo, Nicoletta